Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review
Document Type
Article
Publication Date
2-1-2024
Abstract
Colorectal cancer (CRC) continues to be one of the most prevalent and deadliest forms of cancer worldwide, despite notable advancements in its management. The prognosis for metastatic CRC remains discouraging, with a relative 5 -year survival rate for stage IV CRC patients. Conventional treatments for advanced malignancies such as chemotherapy, often face limitations in effectively targeting cancer cells resulting in off -target distribution and significant side effects. In the quest for better strategies, researchers have explored numerous alternatives. Among these, nanoparticles (NPs) specifically liposomes have emerged as one of the most promising candidates in developing targeted delivery systems for cancer therapeutics. This review discusses the current approaches employing functionalised liposomes to overcome major biological barriers in therapeutics delivery for CRC treatment. We have also shared our perspectives on the technological development of liposomes for future clinical use and highlighted a few useful insights on the material choices for future research work in CRC.
Keywords
Colorectal cancer, Modified liposomes, Targeted drug delivery system, Stimuli-responsive liposomes, PEGylated liposomes, Active ligand targeting
Divisions
phartech
Funders
Geran Penyelidikan Fakulti Farmasi Universiti Malaya (GPF001E-2020)
Publication Title
International Journal of Pharmaceutics
Volume
651
Publisher
Elsevier
Publisher Location
RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS